On January 7, 2026, Monte Rosa Therapeutics, Inc. reported positive interim results from its Phase 1 study of MRT-8102, showing an 85% reduction in hsCRP levels in high cardiovascular disease risk subjects after four weeks, with 94% achieving levels below the risk threshold.